Substance / Medication

Caplacizumab

Overview

Active Ingredient
caplacizumab
RxNorm CUI
2110605

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Efficacy and relative safety of caplacizumab in immune-mediated thrombotic thrombocytopenic purpura: a systematic review and meta-analysis.
Peng Jia-Ying, Wang Si-Yang, Chen Miao-Qi et al. · Blood Coagul Fibrinolysis · 2024
PMID: 38874905Meta-Analysis
Effectiveness and safety of caplacizumab in acquired thrombotic thrombocytopenic purpura: health technology assessment and classification according to the methodology established in Colombia.
Soto-Mora Jahir A, Gómez-Espitia Lina M, Lasalvia Pieralessandro et al. · Int J Technol Assess Health Care · 2023
PMID: 37476982Meta-AnalysisFull text (PMC)
Efficacy and safety of caplacizumab in the treatment of thrombotic thrombocytopenic purpura: a systematic review and meta-analysis.
He Jingyi, Qi Jiaqian, Han Haohao et al. · Expert Rev Hematol · 2023
PMID: 37045600Meta-Analysis
Adding caplacizumab to standard of care in thrombotic thrombocytopenic purpura: a systematic review and meta-analysis.
Djulbegovic Mia, Tong Jiayi, Xu Alice et al. · Blood Adv · 2023
PMID: 36053773Meta-AnalysisFull text (PMC)
Long-term follow-up of patients treated with caplacizumab and safety and efficacy of repeat caplacizumab use: Post-HERCULES study.
Scully Marie, de la Rubia Javier, Pavenski Katerina et al. · J Thromb Haemost · 2022
PMID: 36138517TrialFull text (PMC)
Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura.
Scully Marie, Cataland Spero R, Peyvandi Flora et al. · N Engl J Med · 2019
PMID: 30625070Trial
Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.
Peyvandi Flora, Scully Marie, Kremer Hovinga Johanna A et al. · N Engl J Med · 2016
PMID: 26863353Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Caplacizumab (substance)
SNOMED CT
784411004
UMLS CUI
C3713057
RxNorm CUI
2110605

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.

Caplacizumab: Uses, Evidence & Side Effects | Ltrl